Failures in diagnosis and monitoring plague management of bacterial keratitis

Article

Establishing the correct diagnosis and modifying therapy appropriately based on response are fundamental in the successful management of bacterial keratitis, said Richard L. Abbott, MD, at the World Congress of Ophthalmology.

Establishing the correct diagnosis and modifying therapy appropriately based on response are fundamental in the successful management of bacterial keratitis, said Richard L. Abbott, MD, at the World Congress of Ophthalmology.

"Left untreated, microbial keratitis leads to progressive tissue destruction with potential corneal perforation and extension to adjacent structures. Determining etiology is critical for effective management," said Dr. Abbott, the Thomas W. Boyden Professor of Ophthalmology, Beckman Vision Center, University of California at San Francisco.

In their clinical evaluation, ophthalmologists need to recognize there are many conditions that are masqueraders of bacterial keratitis. Therefore, obtaining a culture with use of proper sampling and plating technique is critical in all suspect cases.

Once treatment is initiated, patients need to be closely observed to determine if the infection is responding, worsening, or if the changing clinical picture is indicative of medication-related toxicity. Dr. Abbott recommended creating a carefully drawn diagram in the chart that includes information about: 1) the depth and density of the infiltration, 2) thinning, 3) the presence and density of white blood cells around the infiltrate, and 4) the size and density of hypopyon. Those features should then be followed in the evaluation of the treatment response.

In the current era, treatment is usually initiated with a fourth-generation fluoroquinolone administered in an intensive regimen for the first several days. Once there is evidence of therapeutic response, the treatment should be tapered to avoid toxicity, but fluoroquinolone administration frequency should never be reduced to below four times a day. When fluoroquinolone discontinuation is deemed appropriate, clinicians who wish to maintain antibiotic coverage may prescribe bacitracin, as that agent offers broad-spectrum activity and is well-tolerated, said Dr. Abbott.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.